Search Results

Site Search

Helicobacter pylori Infection: Serologic Testing Not Recommended [Communiqué] - Insights

Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H...

November 2019 — Molecular Genetics - Insights

1-day-old female born with omphalocel, macroglossia, and enlarged kidneys. Julie Li, B.Med., Ph.D.Fellow, Molecular Genetic PathologyMayo Clinic Matthew

December 2019 — Dermatopathology - Insights

A 7-year old boy presented with growing skin lesion on the back. ( Click on image to view magnified ) ( Click on image to view magnified ) ( Click on

Communique - Insights

Communiqué takes a deep dive into how Mayo Clinic Laboratories advances patient care, research, and education through laboratory medicine. Our experts are solving the most serious and complex medical challenges for patients worldwide.

Membranous nephropathy - Insights

Membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults. Our menu of clinically validated assays assists with diagnosis, monitors disease progression, and guides clinical outcomes.

MayoComplete next-generation sequencing: Transforming comprehensive cancer care - Insights

Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.

New tests launched in July - Insights

In July 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

May and June tests - Insights

In May and June 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

Direct Ethanol Biomarker Testing: PETH - Insights

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for...

Novel malabsorption panel speeds diagnosis - Insights

Puanani Hopson, D.O., explains how Mayo Clinic Laboratories’ malabsorption panel can provide timelier diagnosis for children with chronic diarrhea or unexplained weight loss. The novel panel, which bundles four existing tests, requires just...

Precision therapeutics can individualize depression treatment - Insights

Ann Moyer, M.D., Ph.D., and Paul Jannetto, Ph.D., explain how precision therapeutics can improve treatment for patients with major depressive disorder. The optimal antidepressant medication and dose vary among individuals. Pharmacogenomic...

PCD test provides definitive diagnosis of a rare disease - Insights

Joseph Maleszewski, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's...

Neurofilament Light Chain (NFLC) - Insights

Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s...

MCL Additional Specimen MC4091248

MCL Additional Specimen Complete print Additional Specimen Reset Form Instructions form sending additional specimen order

Extended Spectrum Beta Lactamase Testing - Insights

Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool...

TPNUQ genotyping assay - Insights

Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which...

Liquid biopsy offers noninvasive DNA testing for cancer care - Insights

Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation...

Colorectal panel provides detailed cancer information - Insights

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Focused Pharmacogenomics Panel [Test in Focus] - Insights

Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for...

Autoimmune Axonal Evaluation - Insights

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on...

Rare Lyme disease-causing bacteria spotted on routine blood films - Insights

It’s been understood for some time that an infection of B. mayonii, a rare species of bacterium, results in high levels of spirochetes in the peripheral blood. But actually being able to visualize them on a routine peripheral blood smear...

Stiff-Person/PERM Evaluation - Insights

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay...

NB Gaucher (1).pdf

MAYO CLINIC LABORATORIES Newborn Screen Follow-up for Gaucher Disease GBA activity - decreased Glucopsychosine - elevated Gaucher disease confirmed Referral to Genetics Specialist Newborn screen result: decreased beta-glucosidase*...

New tests launched in September - Insights

In September 2022, Mayo Clinic Laboratories announced ten new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

New tests launched in November - Insights

Mayo Clinic Laboratories launched the following three tests in November.

Precision transplant therapeutics - Insights

We offer a precision-driven solution to transplant therapeutics that combines pharmacogenomics, therapeutic drug monitoring, expert clinical support, and decades of leadership and research.

Urinary ammonium testing - Insights

John Lieske, M.D., discusses Mayo Clinic Laboratories' urinary ammonium testing. A test that takes the guesswork out of determining acid base disorders by giving nephrologists a true understanding of a patient’s true urinary ammonium level.

Nonradioactive assay helps diagnose heparin reaction - Insights

Rajiv Pruthi, M.B.B.S., explains how Mayo Clinic Laboratories’ serotonin release assay achieves high sensitivity and specificity while avoiding the use of radioactive materials. Serotonin release testing is an important tool in the...

Comprehensive panel boosts GIST diagnosis sensitivity - Insights

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) - Insights

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide...

Enhanced detection of genetic mutation to optimize leukemia treatment - Insights

Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical...

Melanoma panel provides more tumor information - Insights

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Mass spectrometry-based assay detects viral antigens directly from clinical specimens - Insights

In a newly published study, a team from Mayo Clinic’s Advanced Diagnostics Laboratory has developed a mass spectrometry-based assay that’s able to detect COVID-19 (SARS-CoV-2) pathogens from human proteins with, remarkably, 98% sensitivity...

Mitochondrial Disease [Test in Focus] - Insights

Linda Hasadsri, M.D., Ph.D., explains how Mayo Clinic Laboratories’ inclusive approach to mitochondrial disease testing expedites diagnosis. Using innovative methodologies like custom reagents and droplet digital PCR enables precision...

Unique pediatric evaluation targets relevant autoimmune/CNS antibodies - Insights

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers...

MayoComplete Solid Tumor Panel - Insights

Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.

Autoimmune profile updates - Insights

Based on studies that have shown certain antibodies may not be as clinically relevant to autoimmune testing as previously thought, Mayo Clinic Laboratories is updating a number of its autoimmune profiles by removing some antibodies from...

Myasthenia Gravis [Test in Focus] - Insights

Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in...

West Nile virus [Test in Focus] - Insights

Bobbi Pritt, M.D., discusses how Mayo Clinic Labs’ updated PCR assay for West Nile virus provides increased sensitivity to detect virus RNA in multiple sources, identifies two virus lineages, and confirms diagnosis.

Cayuga Medical Center: Building a world-class lab that drives revenue - Insights

Cayuga Medical Center sought to challenge the narrative that a hospital’s lab is an expensive liability by positioning themselves as the laboratory of choice in their area.

February 2020 — Cytopathology, Clinical Microbiology, Gastroenterology & Infectious Disease - Insights

A 65-year-old man with history of treated anal intraepithelial neoplasia presents with new-onset diarrhea. A Papanicolaou-stained anal smear was performed

MCL Pricing Custom Gene Ordering MC4091141

MCL Pricing Custom Gene Ordering Custom Gene Panel Ordering Pricing Tiers CGPH Custom Gene Panel Hereditary Generation Sequencing NGS Varies Explanation Pricing

MCL Lead and Heavy Metals Reporting MC123569

MCL Lead Heavy Metals Reporting Complete print Lead Heavy Metals Reporting Reset Form information Lead

Improving outcomes through comprehensive controlled substance monitoring - Insights

Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new...

Using metal detectors to ward off wayward specimens - Insights

To safeguard patient samples, staff in Mayo Clinic’s Histology Laboratory devised an inventive way to ensure that none of the paraffin-embedded blocks processed in the lab ever ends up in the trash.

PIK3CA assay guides treatment of progressing breast cancer - Insights

Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.

Hematology Testing - Mayo Clinic Laboratories

Our comprehensive test menu has beencreated to aid in the diagnosis and treatmentselection across the full spectrum of hematologicdisorders.

bile_acid-associated_tests_ordering_guide.pdf

Bile Acid-Associated Tests Ordering Guide Evaluation of Bowel Dysfunction Use to identify individuals with bile acid diarrhea (1) For screening order 7AC4 / 7AC4, Bile Acid Synthesis, Serum (2) For diagnosis order BAMRP / Bile...